Published in Gut Microbes on July 28, 2011
The microbiome in infectious disease and inflammation. Annu Rev Immunol (2012) 3.76
Loss of sex and age driven differences in the gut microbiome characterize arthritis-susceptible 0401 mice but not arthritis-resistant 0402 mice. PLoS One (2012) 1.42
Persistent Organic Pollutants Modify Gut Microbiota-Host Metabolic Homeostasis in Mice Through Aryl Hydrocarbon Receptor Activation. Environ Health Perspect (2015) 1.34
Segmented filamentous bacteria: commensal microbes with potential effects on research. Comp Med (2014) 0.98
Specific microbiota-induced intestinal Th17 differentiation requires MHC class II but not GALT and mesenteric lymph nodes. J Immunol (2014) 0.93
Bacillus subtilis-mediated protection from Citrobacter rodentium-associated enteric disease requires espH and functional flagella. Infect Immun (2011) 0.91
Increased Expression of DUOX2 Is an Epithelial Response to Mucosal Dysbiosis Required for Immune Homeostasis in Mouse Intestine. Gastroenterology (2015) 0.83
Actual concept of "probiotics": is it more functional to science or business? World J Gastroenterol (2013) 0.82
Structural bacterial molecules as potential candidates for an evolution of the classical concept of probiotics. Adv Nutr (2011) 0.77
Parasitic protozoa and interactions with the host intestinal microbiota. Infect Immun (2017) 0.75
Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell (2009) 20.29
Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med (2008) 12.68
The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity (2009) 8.95
Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol (2009) 6.10
Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci U S A (2004) 5.93
Cytoskeletal rearrangements accompanying salmonella entry into epithelial cells. J Cell Sci (1991) 4.18
Influences of microbiota on intestinal immune system development. Am J Clin Nutr (1999) 3.93
Cytoskeletal composition of attaching and effacing lesions associated with enteropathogenic Escherichia coli adherence to HeLa cells. Infect Immun (1992) 3.82
Segmented filamentous bacteria are potent stimuli of a physiologically normal state of the murine gut mucosal immune system. Infect Immun (1999) 3.45
Differential roles of segmented filamentous bacteria and clostridia in development of the intestinal immune system. Infect Immun (1999) 3.03
Comparison of 16S rRNA sequences of segmented filamentous bacteria isolated from mice, rats, and chickens and proposal of "Candidatus Arthromitus". Int J Syst Bacteriol (1995) 2.39
Segmented filamentous bacteria in a defined bacterial cocktail induce intestinal inflammation in SCID mice reconstituted with CD45RBhigh CD4+ T cells. Inflamm Bowel Dis (2007) 1.73
Segmented filamentous bacteria prevent colonization of enteropathogenic Escherichia coli O103 in rabbits. J Infect Dis (2000) 1.64
The attachment of filamentous segmented micro-organisms to the distal ileum wall of the mouse: a scanning and transmission electron microscopy study. Lab Anim (1987) 1.37
Segmented filamentous bacteria take the stage. Mucosal Immunol (2010) 1.37
Development and maintenance of the gut-associated lymphoid tissue (GALT): the roles of enteric bacteria and viruses. Dev Immunol (1998) 1.33
Alternatives to binary fission in bacteria. Nat Rev Microbiol (2005) 1.33
Actin accumulation at sites of attachment of indigenous apathogenic segmented filamentous bacteria to mouse ileal epithelial cells. Infect Immun (1993) 1.32
Interactions between gut-associated lymphoid tissue and colonization levels of indigenous, segmented, filamentous bacteria in the small intestine of mice. Can J Microbiol (1998) 1.22
Transmission electron microscopic demonstration of phagocytosis and intracellular processing of segmented filamentous bacteria by intestinal epithelial cells of the chick ileum. Infect Immun (2000) 1.17
Effect of penicillin on the succession, attachment, and morphology of segmented, filamentous microbes in the murine small bowel. Infect Immun (1976) 1.14
MICROBIC PHAGOCYTOSIS BY ENTERIC EPITHELIAL CELLS. JAMA (1965) 0.91
Electron microscopy of a filamentous, segmented bacterium attached to the small intestine of mice from a laboratory animal colony in Denmark. Acta Pathol Microbiol Scand B (1979) 0.89
A strain of Lactobacillus plantarum affects segmented filamentous bacteria in the intestine of immunosuppressed mice. FEMS Microbiol Ecol (2008) 0.86
Scanning and transmission electron microscopic observations of bacteria adhering to ileal epithelial cells in growing broiler and White Leghorn chickens. Br Poult Sci (1990) 0.82
Histopathology and ultrastructure of segmented filamentous bacteria-associated rainbow trout gastroenteritis. Vet Pathol (2010) 0.79
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol (2009) 3.18
The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut (2007) 3.15
Glaucoma and Helicobacter pylori: eyes wide shut? Dig Liver Dis (2012) 2.10
Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol (2009) 2.09
Susceptibility of Helicobacter pylori to metronidazole. Am J Gastroenterol (2003) 1.98
Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ (2013) 1.74
Quantification of serum levels of pepsinogens and gastrin to assess eradication of Helicobacter pylori. Clin Gastroenterol Hepatol (2010) 1.58
Are Helicobacter species and enterotoxigenic Bacteroides fragilis involved in inflammatory bowel disease? Dig Dis Sci (2004) 1.51
Intestinal tuberculosis. Curr Opin Infect Dis (2009) 1.47
A comparison amongst three rapid urease tests to diagnose Helicobacter pylori infection in 375 consecutive dyspeptic. Intern Emerg Med (2010) 1.46
Helicobacter pylori and pancreatic disease. JOP (2003) 1.43
Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease. Intern Emerg Med (2011) 1.42
Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population. Intern Emerg Med (2010) 1.40
Inflammatory bowel disease: is the intestine a Trojan horse? Sci Prog (2002) 1.22
Diagnosis of Helicobacter pylori: invasive and non-invasive tests. Best Pract Res Clin Gastroenterol (2007) 1.19
Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. J Antimicrob Chemother (2009) 1.16
Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol (2009) 1.15
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol (2001) 1.14
Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis (2006) 1.11
Precise role of H pylori in duodenal ulceration. World J Gastroenterol (2006) 1.11
Helicobacter: a paradigm shift in peptic ulcer disease and more? Sci Prog (2002) 1.09
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies. J Pharmacol Exp Ther (2007) 1.09
Anxiolytic-like effect of neuropeptide S in the rat defensive burying. Peptides (2008) 1.08
Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists. J Med Chem (2009) 1.08
Ultrastructural study on the body surface of the acanthocephalan parasite Dentitruncus truttae in brown trout. Microsc Res Tech (2008) 1.07
Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis. J Pathol (2004) 1.06
Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori. World J Gastroenterol (2005) 1.05
Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain (2009) 1.05
Does Helicobacter pylori really cause duodenal ulcers? No. BMJ (2009) 1.05
In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. J Pharmacol Exp Ther (2008) 1.05
Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy? J Pharmacol Exp Ther (2003) 1.03
High correlation of babA 2-positive strains of Helicobacter pylori with the presence of gastric cancer. Intern Emerg Med (2011) 1.01
Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol (2004) 1.00
Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med (2012) 0.99
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies. J Pharmacol Exp Ther (2007) 0.95
A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study. Eur J Gastroenterol Hepatol (2012) 0.95
Widespread occurrence of Mycobacterium tuberculosis DNA from 18th-19th century Hungarians. Am J Phys Anthropol (2003) 0.95
A new ligand for the urotensin II receptor. Br J Pharmacol (2002) 0.95
Helicobacter pylori and gastric cancer: neither friend nor foe. Gastroenterology (2007) 0.94
The A2143G point mutation of clarithromycin resistance affects Helicobacter pylori eradication. J Clin Gastroenterol (2009) 0.93
Treatment for H. pylori infection: new challenges with antimicrobial resistance. J Clin Gastroenterol (2013) 0.93
High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. J Gastrointestin Liver Dis (2012) 0.92
Innate immunity and pathogen-host interaction. Vaccine (2003) 0.91
Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review. J Clin Gastroenterol (2013) 0.91
Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol (2004) 0.91
Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol (2012) 0.91
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J Neurochem (2004) 0.89
In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803). Br J Pharmacol (2006) 0.89
Role of noninvasive tests (C-urea breath test and stool antigen test) as additional tools in diagnosis of Helicobacter pylori infection in patients with atrophic body gastritis. Helicobacter (2004) 0.87
CagA and VacA are immunoblot markers of past Helicobacter pylori infection in atrophic body gastritis. Helicobacter (2007) 0.87
Helicobacter pylori antigen stool test and 13C-urea breath test in patients after eradication treatments. Am J Gastroenterol (2002) 0.87
Ligands raise the constraint that limits constitutive activation in G protein-coupled opioid receptors. J Biol Chem (2013) 0.86
Minimal inhibitory concentration (MIC) values and different point mutations in the 23S rRNA gene for clarithromycin resistance in Helicobacter pylori. Dig Liver Dis (2009) 0.86
Newer agents for Helicobacter pylori eradication. Clin Exp Gastroenterol (2012) 0.86
Cross-sectional study: CagA-positive Helicobacter pylori infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide. J Clin Pathol (2013) 0.86
Modified sequential therapy regimens for Helicobacter pylori eradication: a systematic review. Dig Liver Dis (2012) 0.84
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha,alpha-dialkylated amino acids. Bioorg Med Chem (2007) 0.84
Treatment of Helicobacter pylori infection 2014. Helicobacter (2014) 0.84
Controversies in the Helicobacter pylori/duodenal ulcer story. Trans R Soc Trop Med Hyg (2008) 0.83
The paraventricular nucleus of the hypothalamus is a neuroanatomical substrate for the inhibition of palatable food intake by neuropeptide S. Eur J Neurosci (2009) 0.83
Cholera-like enterotoxins and Regulatory T cells. Toxins (Basel) (2010) 0.82
The interaction of highly helical structural mutants with the NOP receptor discloses the role of the address domain of nociceptin/orphanin FQ. Chemistry (2005) 0.82
Presence of Helicobacter pylori in betel chewers and non betel chewers with and without oral cancers. BMC Oral Health (2009) 0.82
Actual concept of "probiotics": is it more functional to science or business? World J Gastroenterol (2013) 0.82
Nociceptin/orphanin FQ receptor activation decreases the airway hyperresponsiveness induced by allergen in sensitized mice. Am J Physiol Lung Cell Mol Physiol (2013) 0.82
A human domain antibody and Lewis b glycoconjugate that inhibit binding of Helicobacter pylori to Lewis b receptor and adhesion to human gastric epithelium. J Infect Dis (2009) 0.81
Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux. Br J Pharmacol (2005) 0.81
Change of point mutations in Helicobacter pylori rRNA associated with clarithromycin resistance in Italy. J Med Microbiol (2013) 0.80
Non-invasive tests for the diagnosis of H. pylori infection. Rev Gastroenterol Disord (2004) 0.80
Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. J Antimicrob Chemother (2003) 0.80
Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. Urology (2003) 0.80
Local in vivo administration of a decoy oligonucleotide targeting NF-kappaB induces apoptosis of osteoclasts after application of orthodontic forces to rat teeth. Int J Mol Med (2006) 0.80
Helicobacter pylori virulence factors in duodenal ulceration: A primary cause or a secondary infection causing chronicity. World J Gastroenterol (2006) 0.80
A validation study of the Italian Short-Form Leeds Dyspepsia Questionnaire. Intern Emerg Med (2010) 0.79
Nociceptin modulates bronchoconstriction induced by sensory nerve activation in mouse lung. Am J Respir Cell Mol Biol (2009) 0.79
Comparison of image analysis software packages in the assessment of adhesion of microorganisms to mucosal epithelium using confocal laser scanning microscopy. J Microbiol Methods (2005) 0.79
Sequential therapy for Helicobacter pylori: time to consider making the switch? JAMA (2008) 0.78
Neuropeptide S inhibits stress-stimulated faecal output in the rat. Pharmacol Res (2011) 0.78
Errors in a meta-analysis of treatments for Helicobacter pylori infection. Ann Intern Med (2008) 0.77
Structural bacterial molecules as potential candidates for an evolution of the classical concept of probiotics. Adv Nutr (2011) 0.77
Treatment of Helicobacter pylori in Latin America. Lancet (2012) 0.77
In vitro binding and functional studies of Ac-RYYRIK-ol and its derivatives, novel partial agonists of the nociceptin/orphanin F/Q receptor. Neurosignals (2006) 0.77
How long will it take to reduce gastric cancer incidence by eradicating Helicobacter pylori infection? Cancer Prev Res (Phila) (2013) 0.77
Efficacy of 5-ASA in the treatment of colonic diverticular disease. J Clin Gastroenterol (2010) 0.77
Hyaluronic acid induces activation of the κ-opioid receptor. PLoS One (2013) 0.77
A new 24 h ELISA culture based method for Helicobacter pylori chemosusceptibility. J Clin Pathol (2010) 0.77
Accuracy of urea breath tests tablets after 10 minutes compared with standard 30 minutes to diagnose and monitoring Helicobacter pylori infection: a randomized controlled trial. J Clin Gastroenterol (2009) 0.77
Use of a single biopsy specimen for diagnosing Helicobacter pylori infection by culture and two different PCR methods: report from Cuba. Trop Gastroenterol (2010) 0.77